Drug intelligence / Profile preview

LY4006895

Development stage: Phase 1
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Intravenous

Overview

LY4006895 is an investigational drug developed by Eli Lilly and Company for the treatment of early symptomatic Alzheimer's disease. It is currently in phase 1 clinical trials, where its safety, tolerability, pharmacokinetics, and pharmacodynamics are being evaluated in both healthy participants and individuals with early symptoms of Alzheimer's disease. The specific mechanism of action for LY4006895 has not been disclosed publicly as of the latest available information. The drug is administered intravenously.

Beyond the preview

Go deeper on LY4006895.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY4006895.

Explore the full profile